ARWR - Arrowhead Pharmaceuticals, Inc.
| Previous Close | 9.53 |
| Open | 9.66 |
| Bid | 10.00 x 1300 |
| Ask | 10.05 x 1000 |
| Day's Range | 9.52 - 10.37 |
| 52 Week Range | 1.42 - 10.37 |
| Volume | 1,964,308 |
| Avg. Volume | 1,507,138 |
| Market Cap | 875.772M |
| Beta | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.48 |
| Earnings Date | Aug 1, 2018 - Aug 6, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.25 |
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of ARWR earnings conference call or presentation 8-May-18 8:30pm GMT
Q2 2018 Arrowhead Pharmaceuticals Inc Earnings Call
- ACCESSWIRE•5 days ago
Wired News – Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases
LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on Arrowhead Pharma, Inc. (NASDAQ: ARWR), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ARWR as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it presented new preclinical data on its expanding pipeline of RNA interference (RNAi) therapeutics for cardiometabolic diseases, including ARO-ANG3 and ARO-APOC3 at the Vascular Discovery: From Genes to Medicine– Scientific Sessions 2018, San Francisco, May 10-12, 2018, a symposium organized by the American Heart Association. Arrowhead intends to file clinical trial applications (CTA) for ARO-ANG3 and ARO-APOC3 before the end of 2018.
- Business Wire•6 days ago
Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV
Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first 3 hepatitis B virus patients in the multiple-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company’s third generation subcutaneously administered RNA interference therapeutic being developed as a potentially curative therapy for patients with chronic HBV infection.
- Motley Fool•8 days ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can the momentum keep going for these sizzling-hot biotech stocks?
- Business Wire•9 days ago
Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline
Arrowhead Pharmaceuticals Inc. today announced the presentation of new preclinical data on its expanding pipeline of RNA interference therapeutics for cardiometabolic diseases, including ARO-ANG3, which targets angiopoietin-like protein 3 , and ARO-APOC3, which targets apolipoprotein C-III .
- MarketWatch•10 days ago
Four momentum stocks to watch amid earnings reports
In focus: Arrowhead Pharmaceuticals, Endocyte, Legacy Reserves and Impinj.
- Benzinga•10 days ago
Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adaptimmune Therapeutics PLC – ...
- GlobeNewswire•11 days ago
Recent Analysis Shows Extreme Networks, Lumber Liquidators, Owens-Illinois, Arrowhead Pharmaceuticals, Intrepid Potash, and General Cable Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, May 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Extreme ...
- Associated Press•12 days ago
Arrowhead Research: Fiscal 2Q Earnings Snapshot
The Pasadena, California-based company said it had a loss of 18 cents per share. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- Business Wire•12 days ago
Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results
Arrowhead Pharmaceuticals Inc. today announced financial results for its fiscal 2018 second quarter ended March 31, 2018. The company is hosting a conference call at 4:30 p.m.
- Business Wire•19 days ago
Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics
Arrowhead Pharmaceuticals Inc. today announced that it will present preclinical data on ARO-ANG3 and ARO-APOC3, its two candidates targeting cardiometabolic diseases, and ARO-ENaC, formerly referred to as ARO-Lung1, its first candidate to leverage the Targeted RNAi Molecule platform to address diseases in the lung.
- Business Wire•26 days ago
Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results
Arrowhead Pharmaceuticals Inc. today announced that it will host a webcast and conference call on May 8, 2018, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2018 second quarter ended March 31, 2018.
- Business Wire•last month
Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™
Arrowhead Pharmaceuticals Inc. today announced the presentation of clinical data on ARC-520, the company’s prior generation investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver Congress™ 2018 , the annual meeting of the European Association for the Study of the Liver .
- Business Wire•2 months ago
Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
Arrowhead Pharmaceuticals Inc. today announced that it will present clinical and pre-clinical data on the company’s investigational medicines for the treatment of chronic hepatitis B infection and liver disease associated with alpha-1 antitrypsin deficiency , at The International Liver Congress™ 2018, the annual meeting of the European Association for the Study of the Liver , being held in Paris from ...
- Business Wire•2 months ago
Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus infection.
- Business Wire•2 months ago
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals Inc. today announced that as an inducement to entering into employment with the Company, on March 16, 2018, the Board of Directors approved "inducement" grants to six new employees under Rule 5635 of the NASDAQ Marketplace Rules.
- Business Wire•2 months ago
Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on Etsy, Tiffany, First BanCorp, Deere, Callaway Golf, and Arrowhead Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Business Wire•2 months ago
Arrowhead to Present at Barclays Global Healthcare Conference 2018
Arrowhead Pharmaceuticals Inc. today announced that the company will make a presentation at the following upcoming event:
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Zosano Pharma
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / U.S. markets rose for the third consecutive session on Monday on the strength of technology shares. The Dow Jones Industrial Average spiked 1.58 percent ...
- Business Wire•3 months ago
Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Arrowhead Pharmaceuticals Inc. today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority and from the local Ethics Committee to proceed with a first-in-human study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
- Business Wire•3 months ago
Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
Arrowhead Pharmaceuticals Inc. today announced the United States Food and Drug Administration has granted orphan drug designation to ARO-AAT, Arrowhead’s second-generation investigational medicine for the treatment of a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.
- Business Wire•3 months ago
Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
Arrowhead Pharmaceuticals Inc. today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority and from the local Ethics Committee to proceed with a first-in-human study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus infection.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ARWR earnings conference call or presentation 9-Feb-18 9:30pm GMT
Q1 2018 Arrowhead Pharmaceuticals Inc Earnings Call
- Associated Press•3 months ago
Arrowhead Research reports 1Q loss
The Pasadena, California-based company said it had a loss of 18 cents per share. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was ...
